GGrantIndex
Sort

8,912 grants matching sars cov 2

NIAID DCR OPERATIONAL TASK ORDERCOVID FUNDING SUPPORTS THE NIAID DCR COVID WEBSITE AND THE VARIANT TESTING SAVE PROGRAM FOR VARIANT TESTING.

$1,200,000
Barry Gause · Leidos Biomedical Research, Inc. · N01 · FY2022 · AI

Structural Characterization of SARS-CoV-2 Genome Organization by NMR

$1,200,000
Tatyana Polenova · University Of Delaware · · FY2023 · BIO

CIVICS PROGRAM - SARS-CoV-2 STUDIES

$1,198,308
Florian Krammer · Icahn School Of Medicine At Mount Sinai · N01 · FY2021 · AI

Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2

$1,197,841
Michael S. Diamond · Washington University · R01 · FY2023 · AI

University of Maryland Claude D. Pepper Older Americans Independence Center (OAIC)

$1,197,554
Alice S. Ryan · University Of Maryland Baltimore · P30 · FY2025 · AG

Cancer Center Support Grant Supplement: Clinical Evaluation of a Q GRFT Nasal Spray for Prevention of SARS-CoV-2

$1,197,257
Robert L Ferris · University Of Pittsburgh At Pittsburgh · P30 · FY2020 · CA

Immunologic Monitoring and Cellular Products Laboratory

$1,197,257
Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · P30 · FY2020 · CA

Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP

$1,197,237
Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI

University of Maryland Claude D. Pepper Older Americans Independence Center (OAIC)

$1,196,757
Jay Steven Magaziner · University Of Maryland Baltimore · P30 · FY2023 · AG

Clinical and Informatics Research on Large Clinical Databases

$1,196,486
Clement McDonald · National Library Of Medicine · ZIA · FY2025 · LM

NSF/MCB-BSF: Sentinels: Viral First Responder Cells (VFRCs) for COVID-19 and Future Rapidly Emerging Infectious Diseases

$1,195,831
Ron Weiss · Massachusetts Institute Of Technology · · FY2021 · BIO

2/2 REPRIEVE Extension for Trial Completion

$1,195,255
Michael Tse-Yin Lu · Massachusetts General Hospital · U24 · FY2024 · HL

Localized mHealth approach to boosting COVID-19 testing and vaccine literacy, access, and uptake among women with criminal legal system involvement

$1,195,191
Jason Edwin Glenn · University Of Kansas Medical Center · U01 · FY2023 · MD

SBIR Phase II: Development of an End-to-End Solution for High-Volume Water Microbiological Testing

$1,194,719
Abdennour Abbas · Frontline Biotechnologies Inc. · · FY2024 · TIP

Sequence analysis of SARS-CoV-2 for rapid identification of novel variants

$1,194,074
National Institute Of Allergy And Infectious Diseases · Y01 · FY2022 · AI

Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2

$1,193,360
Michael S. Diamond · Washington University · R01 · FY2024 · AI

Human antibody-based countermeasures against the Coronavirus SARS-CoV-2

$1,193,309
Michael S. Diamond · Washington University · R01 · FY2020 · AI

University of Maryland Claude D. Pepper Older Americans Independence Center (OAIC)

$1,190,048
Jay Steven Magaziner · University Of Maryland Baltimore · P30 · FY2022 · AG

Using the multiphase optimization strategy (MOST) to optimize an intervention to increase COVID-19 testing for Black and Latino/Hispanic frontline essential workers

$1,188,003
Marya Gwadz · New York University · U01 · FY2023 · MD

Molecular Correlates of Symptom Severity in ME/CFS

$1,186,570
W. Ian Lipkin · Columbia University Health Sciences · U54 · FY2024 · NS

Core D: Clinical Research

$1,186,474
Ighovwerha Ofotokun · Emory University · P30 · FY2022 · AI

Imaging neuroglial mechanisms of neuropathic pain-opioid interaction in HIV

$1,186,451
Marco Luciano Loggia · Massachusetts General Hospital · R01 · FY2022 · DA

Interactions of SARS-CoV-2 N-protein

$1,186,129
Peter Schuck · National Institute Of Biomedical Imaging And Bioengineering · ZIA · FY2023 · EB

SASEA

$1,184,630
Rebecca Kathleen Fielding-Miller · University Of California, San Diego · U01 · FY2023 · HD

Targeting CD180 to induce anti-KSHV response in nonhuman primates

$1,184,569
Scott W Wong · Oregon Health & Science University · U01 · FY2025 · CA